Charles Schwab
VRDN icon

Charles Schwab’s Viridian Therapeutics VRDN Stock Holding History

Charles Schwab’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15M Buy
815,027
+87,090
+12% +$1.4M ﹤0.01% 1967
2026
Q1 		$14.2M Sell
727,937
-21,024
-3% -$624K ﹤0.01% 1929
2025
Q4 		$23.3M Buy
748,961
+153,600
+26% +$4.21M ﹤0.01% 1655
2025
Q3 		$12.8M Buy
595,361
+21,340
+4% +$385K ﹤0.01% 1990
2025
Q2 		$8.02M Buy
574,021
+8,058
+1% +$109K ﹤0.01% 2119
2025
Q1 		$7.63M Sell
565,963
-9,107
-2% -$155K ﹤0.01% 2084
2024
Q4 		$11M Buy
575,070
+58,857
+11% +$1.28M ﹤0.01% 1968
2024
Q3 		$11.7M Buy
516,213
+32,292
+7% +$528K ﹤0.01% 1952
2024
Q2 		$6.3M Buy
483,921
+59,836
+14% +$828K ﹤0.01% 2252
2024
Q1 		$7.43M Buy
424,085
+52,774
+14% +$1.02M ﹤0.01% 2136
2023
Q4 		$8.09M Buy
371,311
+58,094
+19% +$917K ﹤0.01% 2100
2023
Q3 		$4.8M Buy
313,217
+197,430
+171% +$3.77M ﹤0.01% 2280
2023
Q2 		$2.75M Buy
115,787
+11,717
+11% +$301K ﹤0.01% 2455
2023
Q1 		$2.65M Buy
104,070
+1,830
+2% +$58.7K ﹤0.01% 2449
2022
Q4 		$2.99M Buy
102,240
+28,691
+39% +$661K ﹤0.01% 2439
2022
Q3 		$1.51M Buy
73,549
+5,303
+8% +$95.3K ﹤0.01% 2661
2022
Q2 		$790K Buy
+68,246
New +$917K ﹤0.01% 2885
2019
Q2 		– Sell
-3,200
Closed -$134K – 3266
2019
Q1 		$134K Hold
3,200
– – ﹤0.01% 3070
2018
Q4 		$146K Hold
3,200
– – ﹤0.01% 3057
2018
Q3 		$268K Hold
3,200
– – ﹤0.01% 3027
2018
Q2 		$308K Buy
3,200
+873
+38% +$92.3K ﹤0.01% 2953
2018
Q1 		$245K Buy
2,327
+907
+64% +$98.5K ﹤0.01% 2941
2017
Q4 		$223K Hold
1,420
– – ﹤0.01% 2962
2017
Q3 		$195K Hold
1,420
– – ﹤0.01% 3017
2017
Q2 		$276K Buy
+1,420
New +$240K ﹤0.01% 2900

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Charles Schwab's VRDN Position: Q2 2026 in Review

Charles Schwab increased its Viridian Therapeutics (VRDN) stake by 12% in Q2 2026, buying an estimated $1.4M and bringing the position to 815,027 shares worth $15M. The position accounts for ﹤0.01% of the portfolio, ranked #1967.

Charles Schwab first reported a position in VRDN in Q2 2017 and has held it in 25 quarters since. The position peaked at $23.3M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Charles Schwab held 815,027 shares of Viridian Therapeutics worth $15M as of Q2 2026.
  • Charles Schwab bought 87,090 Viridian Therapeutics shares in Q2 2026, an estimated $1.4M.
  • Viridian Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1967 holding.
  • Charles Schwab first reported a position in Viridian Therapeutics in Q2 2017 and has held it in 25 quarters since.
  • Charles Schwab's Viridian Therapeutics position peaked at $23.3M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.